Captain T Cell develops novel immunotherapies for cancer patients with high medical need and very high value creation potential. The team utilizes highly effective TCR-based T cell therapies for this purpose.
Location: Germany
Total raised: $32.63M
Investors 1
| Date | Name | Website |
| 05.05.2024 | BFB Brande... | brandenbur... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.11.2025 | - | $23.39M | - |
| 22.05.2024 | Seed | $9.24M | - |
Mentions in press and media 8
| Date | Title | Description |
| 04.02.2026 | From blood tests to orbital labs: Europe’s next generation of cancer tech | Today, February 4, is World Cancer Day. Cancer kills around 10 million people each year — more than HIV/AIDS, malaria, and tuberculosis combined. Fortunately, European startups are accelerating innovation across the cancer care pipeline, fr... |
| 19.11.2025 | Captain T Cell: €20 Million Funding Raised To Propel Next-Gen Solid Tumor TCR-T Programs Into Clinic | Biotech firm Captain T Cell announced today the successful closing of an equity financing round, bringing its total available funding to €20 million, together with previously secured grants. The funds are earmarked to drive the company’s pr... |
| 17.11.2025 | Captain T Cell Closes Equity Financing Round | Captain T Cell, a Berlin, Germany-based biotechnology company developing TCR-T cell therapies for solid tumors, closed its equity funding. The round was led by Springboard Health Angels and Pluton Asset Holding AG, with participation from S... |
| 22.05.2024 | Captain T Cell's Triumph in Securing Seed Financing Round of €8.5 Million Marks a Milestone in Biotech Innovation | Captain T Cell, a pioneering biotechnology company based in Schoenefeld/Berlin, Germany, has achieved a significant milestone by successfully closing a seed financing round totaling €8.5 million. This achievement was made possible through t... |
| 22.05.2024 | Captain T Cell Secures €8.5M in Seed Financing | Captain T Cell, a Schoenefeld/Berlin, Germany-based biotechnology company developing T cells against solid tumors, raised €8.5M in Seed funding. Backers included i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.... |
| 22.05.2024 | Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million | i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH and HIL-INVENT Ges.m.b.H. participated in the seed round Funds will be used to accelerate a new generation of T cell therapies against solid tumors towards the clinic Schoenefeld/Berlin,... |
| 22.05.2024 | Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million | - |
| - | Captain T Cell | “HOME” |